NASDAQ:CBIO Crescent Biopharma Q4 2025 Earnings Results & Report $14.91 +0.79 (+5.59%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$14.88 -0.03 (-0.17%) As of 10/9/2026 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Crescent Biopharma missed analyst earnings expectations in its Q4 2025 results, released February 26, 2026. The company reported EPS of -$4.01 versus the -$2.22 consensus estimate, while revenue was $10.84 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 26, 2026TimeBefore Market Opens Crescent Biopharma EPS ResultsActual EPS-$4.01Consensus EPS -$2.22Beat/MissMissed by -$1.79One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCrescent Biopharma Revenue ResultsActual Revenue$10.84 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCrescent Biopharma's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Crescent Biopharma Q4 2025 Earnings FAQ Did Crescent Biopharma beat earnings estimates for Q4 2025? Crescent Biopharma (NASDAQ:CBIO) reported earnings of -$4.01 per share for Q4 2025, missing the consensus estimate of -$2.22. The report was announced on Thursday, February 26, 2026. What was Crescent Biopharma's revenue for Q4 2025? Crescent Biopharma reported revenue of $10.84 million for Q4 2025. When is Crescent Biopharma's next earnings date? Crescent Biopharma's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Crescent Biopharma on the company's earnings history page. Crescent Biopharma Earnings HeadlinesCrescent Biopharma (CBIO) Gets a Buy from Stifel NicolausOctober 9 at 7:30 PM | theglobeandmail.comHC Wainwright & Co. upgrades Crescent Biopharma to buy from neutralOctober 6, 2026 | msn.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)Crescent Biopharma Announces Grants of Inducement AwardsOctober 6, 2026 | globenewswire.comCrescent Biopharma Receives FDA Clearance for Investigational New Drug ApplicationOctober 5, 2026 | marketscreener.comMCrescent Biopharma Gets FDA Clearance For Next-Gen Cancer ADC CR-002October 5, 2026 | rttnews.comSee More Crescent Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email. Email Address About Crescent BiopharmaCrescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for serious diseases, with an emphasis on oncology. The company’s activities include drug discovery, preclinical research, clinical development and regulatory advancement of investigational therapies. Crescent Biopharma is focused on advancing its development pipeline and does not appear to have a broad portfolio of marketed products. Publicly available information about the company’s specific drug candidates, geographic operations and leadership is limited.View Crescent Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
